Essential Pharmaceuticals has served the transplant community with its products, service and contributions to transplant medicine since 2006. Custodiol® HTK was initially launched in 2000, but brought into the folds of Essential Pharmaceuticals in 2006. Since 2006, Essential has grown into a significant, highly specialized business with a distinct sales, customer service and marketing team. Custodiol® HTK has grown to be one of the leading organ preservation solutions in the United States.
Essential Pharmaceuticals was acquired by Accord Healthcare in July 2017. Under the terms of the agreement, along with the Essential company, Accord has acquired the rights to sell Custodiol® HTK Solution (www.custodiol.com) in the United States and Canada.